MedTrace Logo

Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction.

NCT03166241 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-05-25

No results posted yet for this study

Summary

Adverse cutaneous drug reactions are undesirable and typically unanticipated reactions independent of the intended therapeutic purpose of a medication. It may be either immunologic (eg, drug allergy) or non-immunologic. Adverse cutaneous drug reaction produce a wide range of clinical manifestations such as pruritus, maculopapular eruptions, urticaria, angioedema, phototoxic and photo allergic reactions, fixed drug reactions, erythema multiforme,vesiculobullous reactions (eg, Stevens-Johnson syndrome and toxic epidermal necrolysis) and serum sickness .They must be considered in the differential diagnosis of sudden symmetric eruption

Conditions

  • Adverse Cutaneous Reaction to Alternative Medical Therapy

Interventions

DIAGNOSTIC_TEST

serum interleukin 21

it is cytokine used as a marker to detect it's level in patients with adverse drug reactions

DIAGNOSTIC_TEST

Complete Blood Picture

It is a blood sample will taken from patients to detect any abnormalities in blood component at the start of the study

DIAGNOSTIC_TEST

Liver function test

It is a blood sample will taken from patients to detect any associated liver disease at the start of the study

DIAGNOSTIC_TEST

Random Blood Sugar

measure blood sugar in patients included in the study at the start of the study

DIAGNOSTIC_TEST

Erythrocyte Sedimentation Rate

blood sample will be taken from patients to detect any abnormalities in erythrocyte sedimentation rate at the start of the study

DIAGNOSTIC_TEST

Kidney function tests

blood sample will be taken from patients to detect any kidney disease before the start of the study

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-31
Primary Completion
2018-07-31
Completion
2018-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03166241 on ClinicalTrials.gov